Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
J Am Acad Dermatol
; 74(1): 81-87.e1, 2016 Jan.
Article
em En
| MEDLINE
| ID: mdl-26601565
ABSTRACT
BACKGROUND:
More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM).OBJECTIVE:
We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod.METHODS:
This was a single-arm, open-label, nonrandomized, prospective study.RESULTS:
Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes.LIMITATIONS:
Our study was a single-center, nonrandomized study.CONCLUSION:
An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Sarda Melanótica de Hutchinson
/
Aminoquinolinas
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Suíça